Development · 5 Nov 2026
LUPIN, full dossier1 publisher has reported this development. Each act of reporting is below, cited.
Lupin is preparing to roll out an oral liquid formulation of apixaban under the 505(b)(2) route in FY28.
A single act of reporting so far, corroborating sources join this record as they publish.
13 Nov 2026 · 1 publisher
11 Nov 2026 · 1 publisher
9 Nov 2026 · 1 publisher
Lupin's Q2-FY27 EBITDA stood at ₹1,960 crore, down 8 per cent year on year.
6 Nov 2026 · 1 publisher
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.